An Efficacy and Safety Evaluation of Montelukast + Fluticasone Propionate Vs Fluticasone Propionate In The Treatment of Cough Variant Asthma In Children: A Meta-Analysis

Authors

Zhengbo Wei
Sheng Li

Language

English

Publication Date

12-5-2023

Journal

BMC Pulmonary Medicine

DOI

10.1186/s12890-023-02721-z

PMID

38053076

PMCID

PMC10696880

PubMedCentral® Posted Date

December 2023

PubMedCentral® Full Text Version

Post-print

Abstract

PURPOSE: This study aimed to evaluate the efficacy and safety of montelukast (Mon) + fluticasone propionate (Flu) versus Flu in the treatment of cough variant asthma (CVA) in children.

METHODS: Eligible documents were selected from various databases. Weighted mean difference (WMD) and 95% confidence interval (CI) were used to evaluate continuous variables, and categorical variables were evaluated using risk ratio (RR) and 95% CI. Heterogeneity analysis was performed using Cochran's Q test and I

RESULTS: Nine studies were included, and Flu + Mon was found to significantly improve the total effective rate and reduce cough recurrence compared to Flu. The cough remission and disappearance times in the Mon + Flu group were significantly lower than those in the Flu group. FEV1% recovery in the Mon + Flu group was significantly better than that in the Flu group.

CONCLUSION: Mon + Flu is effective and safe for the treatment of CVA in children.

Keywords

Child, Humans, Acetates, Anti-Asthmatic Agents, Asthma, Cough, Cyclopropanes, Fluticasone, Quinolines

Published Open-Access

yes

Recommended Citation

Zhengbo Wei and Sheng Li, "An Efficacy and Safety Evaluation of Montelukast + Fluticasone Propionate Vs Fluticasone Propionate In The Treatment of Cough Variant Asthma In Children: A Meta-Analysis" (2023). Faculty, Staff and Student Publications. 2402.
https://digitalcommons.library.tmc.edu/uthmed_docs/2402